Table 1.
Name | Disease | Description | Route of administration | Sponsor | Status | ClinicalTrials.gov Identifier |
---|---|---|---|---|---|---|
FMP012 with AS01B | Malaria | Falciparum malaria protein (FMP012) in a formulation based on liposomes mixed with the immunostimulants monophosphoryl lipid (MPL) and Quillaja saponaria Molina, fraction 21 | Intramuscular injection | US Army Medical Research and GlaxoSmithKline | Phase 1 | NCT02174978 |
| ||||||
TVDV with Vaxfectin [21] | Dengue fever | Tetravalent dengue vaccine (TVDV) with Vaxfectin® cationic lipid-based adjuvant | Intramuscular injection | US Army Medical Research and Materiel Command | Phase 1 | NCT01502358 |
| ||||||
Ag85B-ESAT-6 with CAF01 [22] | Tuberculosis | Subunit protein antigen Ag85B-ESAT-6 with two-component liposomal adjuvant system composed of a cationic liposome vehicle (dimethyldioctadecylammonium (DDA) stabilized with a glycolipid immunomodulator (trehalose 6,6-dibehenate (TDB)) | Intramuscular injection | Statens Serum Institut | Phase 1 | NCT00922363 |
| ||||||
Biocine with lipid A [23] | HIV | Recombinant envelope protein rgp120/HIV-1SF2 combined with lipid A | Intradermal | National Institute of Allergy and Infectious Diseases | Phase 1 | NCT00001042 |
| ||||||
PAMVAC with GLA-SE or GLA-LSQ |
Malaria | Placental malaria vaccine candidate adjuvant with alhydrogel, glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE), or glucopyranosyl lipid adjuvant-liposome-QS-21 formulation (GLA-LSQ) | Intramuscular injection | Tuebingen University Hospital | Phase 1 | NCT02647489 |
| ||||||
ID93 with GLA-SE [24] |
Tuberculosis | Recombinant fusion protein incorporating four M. tuberculosis antigens (ID93) formulated with glucopyranosyl lipid adjuvant- (GLA-) stable emulsion (SE) | Intramuscular injection | National Institute of Allergy and Infectious Diseases | Phase 1 | NCT02508376 |
| ||||||
Novel liposomal based intranasal influenza vaccine | Influenza | Liposomal-based influenza vaccine | Intranasal | Hadassah Medical Organization | Phase 2 | NCT00197301 |
| ||||||
VaxiSome with CCS/C [25] | Influenza | Commercial split influenza virus and polycationic liposome as adjuvant (CCS/C) | Intramuscular injection | NasVax Ltd. | Phase 2 | NCT00915187 |
| ||||||
Fluzone with JVRS-100 [26] | Influenza | Inactivated trivalent influenza virus vaccine administered with cationic lipid-DNA complex adjuvant JVRS-100 | Intradermal | Colby Pharmaceutical Company and Juvaris BioTherapeutics |
Phase 2 | NCT00936468 |
| ||||||
RTS/S with AS01 [27] | Malaria | Repeat sequences of the Plasmodium falciparum circumsporozoite protein (RTS/S) fused to the hepatitis B surface antigen with a liposome-based adjuvant system that also contains monophosphoryl lipid A (MPL) and Quillaja saponaria Molina, fraction 21 | Intramuscular injection | KEMRI-Wellcome Trust Collaborative Research Program and GlaxoSmithKline | Phase 3 | NCT00872963 |
| ||||||
Amphomul [28] | Visceral leishmaniasis | Amphotericin B lipid emulsion | Intramuscular injection | Bharat Serums and Vaccines Limited | Phase 3 | NCT00876824 |